ClinicalTrials.gg
CompletedNCT06294288Updated Dec 12, 2025

A Study of Single and Multiple Doses of LP-003 in Healthy Adult Participants

A Phase 1 interventional study of LP-003 Dose 1 (Single) and LP-003 Dose 2 (Single) in Chronic Spontaneous Urticaria, sponsored by Longbio Pharma. Completed at 1 site in China. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-12.

Sponsored by Longbio Pharma · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 7 months after the study started (first participant enrolled Jul 2022, registered Feb 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 34 studies in Chronic Urticaria with a site in China — 16 open to participants now, 20 under way, 5 of them phase 3. Chronic Urticaria · China.

Enrollment
19th of 30
60 · median 110
Started
2022
with 2 others
Phase 1
7 of 34
3 open now
Registered
12th of 34
by date
Lead sponsor
3 of 34
Longbio Pharma

Among the 34 studies in Chronic Urticaria with a site in China, this one is the 19th largest by enrollment of the 30 interventional ones that give a count, is one of 3 that started in 2022, is one of 7 in phase 1, and was the 12th registered.

Chronic Urticaria

197 studies on the registry are indexed under Chronic Urticaria; 48 are open to participants now.

Browse Chronic Urticaria studies →

Open to participants now

16 of the 34 studies in Chronic Urticaria with a site in China are open now. Recruiting first, the newest first:

11 more — sign in →

All 16 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 25 Chronic Urticaria studies recruiting now, 11 (44%) set no upper age limit and 10 (40%) stop at 75 or younger; 1 takes children under 18; 6 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Chronic Urticaria with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate safety, tolerability, immunogenicity, pharmacokinetics, pharmacodynamics, and efficacy of LP-003 in healthy volunteers. The study will be conducted in 2 parts: Part 1, the single ascending dose (SAD) is the first in human (FIH) study of LP-003 and Part 2, multiple ascending dose (MAD).

03

Conditions studied

  • Chronic Spontaneous Urticaria

Browse trials for

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy males or females aged 18 through 50 years
  2. Male subjects must weigh ≥50 kg, and female subjects must weigh ≥45 kg, with a between 19.0 and 28.0 kg/m² (inclusive).
  3. Male subjects and their partners or female subjects must agree to use one or more non-pharmaceutical methods (such as total abstinence, condoms, Iuds, partner ligation, etc.) during the trial period and for 6 months after the trial, and do not plan to donate sperm or eggs.
  4. The subjects fully understand the purpose, nature, method and possible adverse reactions of the experiment, and voluntarily participate in the experiment and sign the .
  5. The subjects were able to communicate well with the researchers and complete the study according to the protocol.

Exclusion criteria

Exclusion Criteria:

  1. People who are allergic to the experimental drug and any of its , have a history of allergy to monoclonal antibodies, and are allergic to multiple drugs and food.
  2. Patients who have been or are currently suffering from any clinically serious diseases such as circulatory system, endocrine system, nervous system, digestive system, respiratory system, urogenital system, hematology, immunology, psychiatric and metabolic abnormalities, or any other diseases that can interfere with the test results.
  3. Patients who had undergone surgery within 3 months before the trial that the researchers judged would affect drug absorption, distribution, metabolism, and excretion, or had surgery within 4 weeks prior to the trial, or planned to have surgery during the study period.
  4. Any history of infection within 14 days prior to administration.
  5. A person who is currently infected with parasites or has traveled to an endemic area within the last 3 months or 24 weeks prior to administration.
  6. Pregnant and lactating women.
  7. surface antigen, virus antibodies, antibodies, treponema pallidum antibodies A positive person.
  8. Patients who have received any biological agent (including antibodies or derivatives such as omalizumab) within 16 weeks prior to administration (or 5 half-lives, selecting the longer time period).
  9. Participants who had participated in other clinical trials within 3 months prior to screening.
  10. The investigator deems any condition unsuitable for study participation.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Cohort 1: LP-003 Dose 1 (Single)

    Biological: LP-003 Dose 1 (Single)

  • Experimental
    Cohort 2: LP-003 Dose 2 (Single)

    Biological: LP-003 Dose 2 (Single)

  • Experimental
    Cohort 3: LP-003 Dose 3 (Single)

    Biological: LP-003 Dose 3 (Single)

  • Experimental
    Cohort 4: LP-003 Dose 4 (Single)

    Biological: LP-003 Dose 4 (Single)

  • Experimental
    Cohort 5: LP-003 Dose 5 (Single)

    Biological: LP-003 Dose 5 (Single)

  • Placebo comparator
    Cohort 6: Placebo (Single)

    Biological: Placebo (Single)

  • Experimental
    Cohort 7: LP-003 Dose 6 (Multiple)

    Biological: LP-003 Dose 6 (Multiple)

  • Experimental
    Cohort 8: LP-003 Dose 7 (Multiple)

    Biological: LP-003 Dose 7 (Multiple)

  • Experimental
    Cohort 9: LP-003 Dose 8 (Multiple)

    Biological: LP-003 Dose 8 (Multiple)

  • Placebo comparator
    Cohort 10: Placebo (Multiple)

    Biological: Placebo (Multiple)

Interventions

  • A single dose of LP-003 (Dose 1) was administered intravenously.

  • A single dose of LP-003 (Dose 2) was administered intravenously.

  • A single dose of LP-003 (Dose 3) was administered intravenously.

  • A single dose of LP-003 (Dose 4) was administered intravenously.

  • A single dose of LP-003 (Dose 5) was administered intravenously.

  • BiologicalPlacebo (Single)

    A single dose of placebo was administered intravenously.

  • LP-003 (Dose 6) was administered multiple times subcutaneously.

  • LP-003 (Dose 7) was administered multiple times subcutaneously.

  • LP-003 (Dose 8) was administered multiple times subcutaneously.

  • BiologicalPlacebo (Multiple)

    Placebo was administered multiple times subcutaneously.

06

What researchers measure

Primary outcomes

  1. Adverse events

    Number of subjects with treatment-related Treatment Emergent Adverse Events (TEAEs).

    Time frame: Observation for 280 days after administration

Secondary outcomes

  1. Time to peak concentration (Tmax) of LP-003

    The time when the blood drug concentration reaches its peak after a single dose of medication.

    Time frame: Observation for 280 days after administration

  2. Maximum concentration (Cmax) of LP-003

    The maximum concentration of LP-003 in the bloodstream after administration.

    Time frame: Observation for 280 days after administration

  3. Elimination half-life (t1/2) of LP-003

    The time required for the concentration of LP-003 in the bloodstream to decrease by half.

    Time frame: Observation for 280 days after administration

  4. Area under the concentration-time curve (AUC0-t) of LP-003

    The area under the concentration-time curve (AUC) from time zero to the last chosen time point represents the integral of the drug concentration in the bloodstream over the specified duration.

    Time frame: Observation for 280 days after administration

  5. Apparent clearance rate (CL/F) of LP-003

    The ratio of drug clearance to drug concentration, represents the apparent clearance of a drug after administration, adjusted for bioavailability.

    Time frame: Observation for 280 days after administration

  6. Assessment of immunogenicity

    The proportion of anti drug antibody (ADA) positive subjects at different detection time points.

    Time frame: Observation for 280 days after administration

  7. Assessment of total immunoglobulin E (IgE)

    The changes in serum total immunoglobulin E (IgE) levels compared to baseline at different assessment time points.

    Time frame: Observation for 168 days after administration

  8. Assessment of free IgE

    The changes in serum free IgE levels compared to baseline at different assessment time points.

    Time frame: Observation for 168 days after administration

07

Study locations

1 site
  • Shanghai General Hospital
    Shanghai, Shanghai Municipality, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2022 to primary completion in Mar 2024, 19 months.

Of 15 phase 1 interventional studies under Chronic Urticaria, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 21. This study's 19 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2024
First posted
Mar 5, 2024
StartActual
Jul 13, 2022
Primary completionActual
Mar 4, 2024
CompletionActual
Mar 4, 2024
Last update
Dec 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06294288
Lead sponsor
Longbio Pharma
Responsible party
Sponsor
First posted
Mar 5, 2024
Start date
Jul 13, 2022
Primary completion
Mar 4, 2024
Completion
Mar 4, 2024
Last update
Dec 12, 2025

Study contacts

Xueying Ding
principal investigator · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: LP-003

Start the discussion